Publication 論文一覧










-
65.
Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, Obadia T, Robinson LJ, Matsuura F, Liu ZSJ, Li-Wai-Suen CSN, Tham WH, Healer J, Huon C, Chitnis CE, Nguitragool W, Monteiro W, Proietti C, Doolan DL, Siqueira AM, Ding XC, Gonzalez IJ, Kazura J, Lacerda M, Sattabongkot J, Tsuboi T, Mueller I. Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nat Med. 2020 May;26(5):741-749. doi: 10.1038/s41591-020-0841-4. Epub 2020 May 11. PubMed PMID: 32405064.
-
64.
Nagaoka H, Kanoi BN, Ntege EH, Aoki M, Fukushima A, Tsuboi T, Takashima E. Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A. Sci Rep. 2020 Apr 20;10(1):6573. doi: 10.1038/s41598-020-63611-6. PubMed PMID: 32313230; PubMed Central PMCID: PMC7171142.
-
63.
Tougan T, Edula JR, Morita M, Takashima E, Honma H, Tsuboi T, Horii T. The malaria parasite Plasmodium falciparum in red blood cells selectively takes up serum proteins that affect host pathogenicity. Malar J. 2020 Apr 15;19(1):155. doi: 10.1186/s12936-020-03229-1. PubMed PMID: 32295584; PubMed Central PMCID: PMC7161009.
-
62.
Tachibana M, Baba M, Takashima E, Tsuboi T, Torii M, Ishino T. The C-terminal region of the Plasmodium yoelii microgamete surface antigen PyMiGS induces potent anti-malarial transmission-blocking immunity in mice. Vaccine. 2020 Mar 30;38(15):3129-3136. doi: 10.1016/j.vaccine.2020.02.058. Epub 2020 Mar 5. PubMed PMID: 32147299.
-
61.
Lee Y, Yamada H, Pradipta A, Ma JS, Okamoto M, Nagaoka H, Takashima E, Standley DM, Sasai M, Takei K, Yamamoto M. Initial phospholipid-dependent Irgb6 targeting to Toxoplasma gondii vacuoles mediates host defense. Life Sci Alliance. 2020 Jan;3(1). doi: 10.26508/lsa.201900549. Print 2020 Jan. PubMed PMID: 31852733; PubMed Central PMCID: PMC6925386.
-
60.
Nagaoka H, Kanoi BN, Jinoka K, Morita M, Arumugam TU, Palacpac NMQ, Egwang TG, Horii T, Tsuboi T, Takashima E. The N-Terminal Region of Plasmodium falciparum MSP10 Is a Target of Protective Antibodies in Malaria and Is Important for PfGAMA/PfMSP10 Interaction. Front Immunol. 2019;10:2669. doi: 10.3389/fimmu.2019.02669. eCollection 2019. PubMed PMID: 31824483; PubMed Central PMCID: PMC6880778.
-
59.
Miura K, Tachibana M, Takashima E, Morita M, Kanoi BN, Nagaoka H, Baba M, Torii M, Ishino T, Tsuboi T. Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development. Expert Rev Vaccines. 2019 Oct;18(10):1017-1027. doi: 10.1080/14760584.2019.1674145. Epub 2019 Oct 10. Review. PubMed PMID: 31566026.
-
58.
Nagaoka H, Sasaoka C, Yuguchi T, Kanoi BN, Ito D, Morita M, Udomsangpetch R, Sattabongkot J, Ishino T, Tsuboi T, Takashima E. PfMSA180 is a novel Plasmodium falciparum vaccine antigen that interacts with human erythrocyte integrin associated protein (CD47). Sci Rep. 2019 Apr 11;9(1):5923. doi: 10.1038/s41598-019-42366-9. PubMed PMID: 30976034; PubMed Central PMCID: PMC6459815.
-
57.
Yusuf Y, Yoshii T, Iyori M, Yoshida K, Mizukami H, Fukumoto S, Yamamoto DS, Alam A, Emran TB, Amelia F, Islam A, Otsuka H, Takashima E, Tsuboi T, Yoshida S. Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming. Front Immunol. 2019;10:730. doi: 10.3389/fimmu.2019.00730. eCollection 2019. PubMed PMID: 31024558; PubMed Central PMCID: PMC6460511.
-
56.
Tohmoto T, Takashima E, Takeo S, Morita M, Nagaoka H, Udomsangpetch R, Sattabongkot J, Ishino T, Torii M, Tsuboi T. Anti-MSP11 IgG inhibits Plasmodium falciparum merozoite invasion into erythrocytes in vitro. Parasitol Int. 2019 Apr;69:25-29. doi: 10.1016/j.parint.2018.10.012. Epub 2018 Oct 30. PubMed PMID: 30385417.
